BRCA1 and breast carcinoma: Generally, TNBC associated with BRCA1 or BRCA2 mutant is currently the only type sensitive to targeted therapy, approximately 5% of patients with breast cancer carry germline mutations in BRCA1 or BRCA2 (55, 56).